Drug profile · INN
quizartinib
VANFLYTA
quizartinib (VANFLYTA) is a platelet-derived growth factor receptor inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01EX11
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — quizartinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
quizartinib (VANFLYTA) is a platelet-derived growth factor receptor inhibitor.
Key facts
INN quizartinib
Brand VANFLYTA
Mechanism Platelet-derived growth factor receptor inhibitor
Target Macrophage colony-stimulating factor 1 receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX11
Mechanism of action
Platelet-derived growth factor receptor inhibitor
Primary target: Macrophage colony-stimulating factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is quizartinib?
quizartinib (VANFLYTA) is a platelet-derived growth factor receptor inhibitor.
What is the brand name for quizartinib?
VANFLYTA is a marketed brand name for quizartinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.